Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitomycin-C Intravascular Chemoembolization for Corneal Neovascularization
TCTR20261104001Phase 1Not yet recruiting
- Sponsor
- Chalisa Jitudomtham
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mitomycin c in corneal neovascularization (CNV) (2 arms), sponsored by Chalisa Jitudomtham. Primary endpoint: 50% reduction in corneal neovascular area. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
mitomycin c
03
Conditions
corneal neovascularization (CNV)
Beyond the preview
Go deeper on TCTR20261104001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20261104001.